A Phase Ib/II, open-label, multicenter, randomized clinical trial to evaluate atezolizumab in combination with PEGPH20 in the treatment metastatic pancreatic ductal adenocarcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 13 Jul 2017 Status changed from planning to recruiting, according to a Halozyme Therapeutics media release.
- 28 Nov 2016 New trial record
- 10 Nov 2016 According to Halozyme Therapeutics media release, this study is expected in the beginning in 2017.